See more : Rubicon Technologies, Inc. (RBT) Income Statement Analysis – Financial Results
Complete financial analysis of Inventiva S.A. (IVA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inventiva S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xuchang Yuandong Drive Shaft Co.Ltd (002406.SZ) Income Statement Analysis – Financial Results
- Nation International Edutainment Public Company Limited (NINE.BK) Income Statement Analysis – Financial Results
- Eve Holding, Inc. (EVEX) Income Statement Analysis – Financial Results
- Ringmetall AG (HP3.DE) Income Statement Analysis – Financial Results
- Herantis Pharma Oyj (HRTIS.HE) Income Statement Analysis – Financial Results
Inventiva S.A. (IVA)
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.48M | 12.18M | 4.19M | 372.00K | 7.00M | 3.20M | 6.52M | 9.45M | 4.87M | 3.28M | 3.06M |
| Cost of Revenue | -23.00K | 995.00K | 1.02M | 846.00K | 0.00 | 967.00K | 1.24M | 1.49M | 1.40M | 1.52M | 1.68M |
| Gross Profit | 17.50M | 11.18M | 3.18M | -474.00K | 7.00M | 2.23M | 5.28M | 7.96M | 3.47M | 1.76M | 1.38M |
| Gross Profit Ratio | 100.13% | 91.83% | 75.75% | -127.42% | 100.00% | 69.75% | 81.05% | 84.27% | 71.18% | 53.59% | 45.11% |
| Research & Development | 110.01M | 60.47M | 48.45M | 23.72M | 33.79M | 31.64M | 26.73M | 22.14M | 19.64M | 16.28M | 13.75M |
| General & Administrative | 13.85M | 12.91M | 11.16M | 8.50M | 4.51M | 4.51M | 4.09M | 3.25M | 3.11M | 2.65M | 2.71M |
| Selling & Marketing | 1.76M | 2.58M | 364.00K | 563.00K | 8.00K | 9.00K | 37.78K | 50.56K | 112.70K | 247.32K | 325.57K |
| SG&A | 15.61M | 15.50M | 11.52M | 9.06M | 4.51M | 4.52M | 4.12M | 3.30M | 3.22M | 2.90M | 3.04M |
| Other Expenses | -5.43M | -6.68M | -3.66M | -2.69M | -2.09M | 257.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Cost & Expenses | 120.19M | 69.29M | 56.31M | 30.09M | 36.21M | 36.42M | 26.99M | 21.49M | 19.75M | 16.75M | 15.53M |
| Interest Income | 945.00K | 390.00K | 5.48M | 226.00K | 157.00K | 120.00K | 276.62K | 230.18K | 227.63K | 273.84K | 42.65K |
| Interest Expense | 5.18M | 707.00K | 2.64M | 66.00K | 3.00K | 4.00K | 5.32K | 7.55K | 6.06K | 2.94K | 630.00 |
| Depreciation & Amortization | 2.60M | 1.68M | 927.00K | 1.01M | 1.46M | 949.00K | 1.24M | 1.49M | 1.30M | 1.23M | 1.38M |
| EBITDA | -102.04M | -57.11M | -52.27M | -31.78M | -28.36M | -32.04M | -22.00M | -11.14M | -13.91M | -12.43M | -11.42M |
| EBITDA Ratio | -583.86% | -468.92% | -1,111.99% | -7,988.71% | -392.90% | -969.50% | -287.82% | -104.86% | -268.39% | -349.37% | -337.41% |
| Operating Income | -102.71M | -57.11M | -52.11M | -29.72M | -30.31M | -33.25M | -20.92M | -13.02M | -15.51M | -13.47M | -12.47M |
| Operating Income Ratio | -587.68% | -468.92% | -1,242.58% | -7,988.71% | -433.15% | -1,040.13% | -320.76% | -137.83% | -318.17% | -410.22% | -406.81% |
| Total Other Income/Expenses | -7.11M | 2.82M | 2.84M | -3.90M | 95.00K | -111.00K | 278.00K | 460.23K | 486.14K | 745.10K | 748.35K |
| Income Before Tax | -109.82M | -54.29M | -49.27M | -33.62M | -30.22M | -33.36M | -20.64M | -12.56M | -15.02M | -12.72M | -11.72M |
| Income Before Tax Ratio | -628.36% | -445.80% | -1,174.82% | -9,037.63% | -431.79% | -1,043.57% | -316.49% | -132.96% | -308.20% | -387.52% | -382.39% |
| Income Tax Expense | 607.00K | -20.00K | 364.00K | -2.00M | 4.00K | 253.00K | -3.41M | -5.51M | -6.20M | -5.23M | -4.58M |
| Net Income | -110.43M | -54.27M | -49.64M | -31.62M | -30.22M | -33.62M | -17.23M | -7.05M | -8.82M | -7.49M | -7.13M |
| Net Income Ratio | -631.84% | -445.64% | -1,183.50% | -8,500.81% | -431.85% | -1,051.49% | -264.22% | -74.59% | -181.00% | -228.26% | -232.82% |
| EPS | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| EPS Diluted | -2.43 | -1.31 | -1.27 | -0.93 | -1.28 | -1.64 | -1.11 | -0.45 | -0.88 | -0.75 | -0.71 |
| Weighted Avg Shares Out | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.68M | 10.03M | 10.03M | 10.03M |
| Weighted Avg Shares Out (Dil) | 45.35M | 41.45M | 39.17M | 33.87M | 23.52M | 20.54M | 15.52M | 15.74M | 10.03M | 10.03M | 10.03M |
Inventiva reports 2024 Third Quarter Financial Information¹
Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),...
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),...
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated...
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of...
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of...
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of...
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of...
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Source: https://incomestatements.info
Category: Stock Reports